$TNFA
TNF Pharmaceuticals, Inc. Stock $tnfa

$tnfa Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022611 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.907M	$1.479M	$1.492M
YoY Change	16.22%	-91.17%	-1.18%
% of Gross Profit
Research & Development	$1.803M	$2.164M	$2.630M
YoY Change	-34.85%	30.26%	-13248.7%
% of Gross Profit
Depreciation & Amortization		$0.00
YoY Change
% of Gross Profit
Operating Expenses	$1.803M	$2.164M	$4.122M
YoY Change	-59.09%	30.26%	176.63%
Operating Profit	-$3.710M	-$3.643M	-$4.122M
YoY Change	-15.84%	-80.07%	176.63%
Interest Expense	$16.15K	$6.930K	-$4.620K
YoY Change	-1731.31%	-119.86%	-115.4%
% of Operating Profit
Other Income/Expense, Net	$16.15K	$6.934K	-$180.00
YoY Change	-101.53%	-96.27%
Pretax Income	-$3.694M	-$3.636M	-$4.122M
YoY Change	-32.44%	-79.9%	184.28%
Income Tax
% Of Pretax Income
Net Earnings	-$3.694M	-$3.636M	-$4.122M
YoY Change	-32.44%	-79.9%	33.41%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.09	-$0.09	-$0.11
Diluted Earnings Per Share	-$94.60K	-$94.87K	-$108.1K
COMMON SHARES
Basic Shares Outstanding	38.06M shares	38.33M shares	38.12M shares
Diluted Shares Outstanding	39.05M shares	38.33M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.084M	$5.621M	$9.188M
YoY Change	-53.93%	-74.01%	-70.41%
Cash & Equivalents	$309.9K	$1.115M	$1.189M
Short-Term Investments	$6.774M	$4.506M	$7.999M
Other Short-Term Assets	$993.1K	$1.371M	$884.1K
YoY Change	74.29%	84.19%	301.87%
Inventory
Prepaid Expenses	$993.1K	$1.371M
Receivables
Other Receivables
Total Short-Term Assets	$8.077M	$6.992M	$10.07M
YoY Change	-49.35%	-68.75%	-70.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$155.1K	$170.2K	$132.8K
YoY Change	141.52%	127.37%
Goodwill	$10.50M	$10.50M
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.500M	$1.500M	$1.500M
YoY Change	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$12.15M	$12.17M	$12.13M
YoY Change	0.75%	0.79%	708.75%
TOTAL ASSETS
Total Short-Term Assets	$8.077M	$6.992M	$10.07M
Total Long-Term Assets	$12.15M	$12.17M	$12.13M
Total Assets	$20.23M	$19.16M	$22.20M
YoY Change	-27.77%	-44.38%	-37.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.717M	$2.842M	$1.996M
YoY Change	-16.37%	-13.86%	-14.7%
Accrued Expenses	$324.6K	$223.4K	$470.7K
YoY Change	733.89%	351.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.781M	$2.903M	$2.467M
YoY Change	-14.89%	-13.29%	4.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$123.1K	$139.8K	$114.6K
YoY Change	373.94%	440.7%
Total Long-Term Liabilities	$123.1K	$139.8K	$114.6K
YoY Change	373.93%	440.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.781M	$2.903M	$2.467M
Total Long-Term Liabilities	$123.1K	$139.8K	$114.6K
Total Liabilities	$1.904M	$3.043M	$2.581M
YoY Change	-10.12%	-9.82%	8.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$90.01M	-$86.32M
YoY Change
Common Stock	$108.2M	$102.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.33M	$16.12M	$19.62M
YoY Change
Total Liabilities & Shareholders Equity	$20.23M	$19.16M	$22.20M
YoY Change	-27.77%	-44.38%	-37.98%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.694M	-$3.636M	-$4.122M
YoY Change	-32.44%	-79.9%	33.41%
Depreciation, Depletion And Amortization		$0.00
YoY Change
Cash From Operating Activities	-$4.087M	-$3.568M	-$2.366M
YoY Change	-36.59%	-38.25%	-4.59%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$2.268M	$3.494M	$2.999M
YoY Change	-141.25%	-87.02%	-119.26%
Cash From Investing Activities	-$2.268M	$3.494M	$2.999M
YoY Change	-141.25%	-87.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.550M	0.000
YoY Change	2748.07%	-100.0%
NET CHANGE
Cash From Operating Activities	-4.087M	-3.568M	-2.366M
Cash From Investing Activities	-2.268M	3.494M	2.999M
Cash From Financing Activities	5.550M	0.000
Net Change In Cash	-805.2K	-74.06K	$0.00
YoY Change	7.03%	-100.37%
FREE CASH FLOW
Cash From Operating Activities	-$4.087M	-$3.568M	-$2.366M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	MYMD	Interest Expense Accretion Of Debt Discount InterestExpenseAccretionOfDebtDiscount		usd
	MYMD	Interest Expense Accretion Of Debt Discount InterestExpenseAccretionOfDebtDiscount		usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	MYMD	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Or Expired In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001321834
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2022Q2	us-gaap	Gross Profit GrossProfit		usd
CY2021Q2	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2022Q2	MYMD	Gain On Debt Forgiveness GainOnDebtForgiveness		usd
	MYMD	Gain On Debt Forgiveness GainOnDebtForgiveness		usd
CY2022Q2	MYMD	Gain Loss On Uninsured Casualty GainLossOnUninsuredCasualty		usd
CY2021Q2	MYMD	Gain Loss On Uninsured Casualty GainLossOnUninsuredCasualty		usd
	MYMD	Gain Loss On Uninsured Casualty GainLossOnUninsuredCasualty		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	MYMD	Exercise Of Prepaid Equity Forward Contracts For Common Stock ExerciseOfPrepaidEquityForwardContractsForCommonStock		usd
CY2021Q2	MYMD	Exercise Of Prepaid Equity Forward Contracts For Common Stock ExerciseOfPrepaidEquityForwardContractsForCommonStock		usd
	MYMD	Accrued Interestdividends AccruedInterestdividends		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	MYMD	Stock Option Modification Expenses StockOptionModificationExpenses		usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense		usd
	MYMD	Options Issued To Nonemployees OptionsIssuedToNonemployees		usd
	MYMD	Restricted Stock Units To Nonemployees RestrictedStockUnitsToNonemployees		usd
	MYMD	Net Cash Received In Business Combination NetCashReceivedInBusinessCombination		usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	MYMD	Other Asset Investment OtherAssetInvestment		usd
CY2021Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	41447	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	41447	usd
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36268
	dei	Entity Registrant Name EntityRegistrantName	MyMD Pharmaceuticals, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NJ
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-2983783
	dei	Entity Address Address Line1 EntityAddressAddressLine1	855 N. Wolfe Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 601
	dei	Entity Address City Or Town EntityAddressCityOrTown	Baltimore
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	21205
	dei	City Area Code CityAreaCode	(856)
	dei	Local Phone Number LocalPhoneNumber	848-8698
	dei	Security12b Title Security12bTitle	Common Stock, no par value per share
	dei	Trading Symbol TradingSymbol	MYMD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38058245	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1115174	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	555967	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4505825	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11003071	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1371407	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1106347	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	6992406	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	12665385	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	170226	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	149009	usd
CY2022Q2	us-gaap	Goodwill Goodwill	10498539	usd
CY2021Q4	us-gaap	Goodwill Goodwill	10498539	usd
CY2022Q2	us-gaap	Long Term Investments LongTermInvestments	1500000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	1500000	usd
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	12168765	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	12147548	usd
CY2022Q2	us-gaap	Assets Assets	19161171	usd
CY2021Q4	us-gaap	Assets Assets	24812933	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2841535	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	986626	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	61519	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	53240	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2903054	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1039866	usd
CY2022Q2	MYMD	Due To Shareholders Non Current DueToShareholdersNonCurrent	29982	usd
CY2021Q4	MYMD	Due To Shareholders Non Current DueToShareholdersNonCurrent	29982	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	109792	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	95911	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	139774	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	125893	usd
CY2022Q2	us-gaap	Liabilities Liabilities	3042828	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1165759	usd
CY2022Q2	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2021Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	144524	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	144524	usd
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38058245	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38058245	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37673110	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37673110	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	102293464	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	102064218	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86319645	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78561568	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16118343	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23647174	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19161171	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24812933	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1346763	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1540392	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2741875	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2618555	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2163968	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1661265	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4793711	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3012242	usd
CY2021Q2	MYMD	Interest Expense Accretion Of Debt Discount InterestExpenseAccretionOfDebtDiscount	40526	usd
	MYMD	Interest Expense Accretion Of Debt Discount InterestExpenseAccretionOfDebtDiscount	701090	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	132246	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	15036051	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	229245	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	15036051	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3642977	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18278234	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7764831	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21367938	usd
CY2022Q2	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	5986	usd
CY2021Q2	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	5641	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	6106	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	5641	usd
CY2022Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-1999	usd
CY2021Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	41447	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-3649	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	41447	usd
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	2947	usd
CY2021Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-41447	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-145	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-41447	usd
CY2021Q2	MYMD	Gain On Debt Forgiveness GainOnDebtForgiveness	180257	usd
	MYMD	Gain On Debt Forgiveness GainOnDebtForgiveness	180257	usd
	MYMD	Gain Loss On Uninsured Casualty GainLossOnUninsuredCasualty	4442	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6934	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	185898	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6754	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	185898	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3636043	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18092336	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7758077	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21182040	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3636043	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-18092336	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7758077	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21182040	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.09
CY2021Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.50
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.20
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.66
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38325311	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35906891	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38224679	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32250413	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23647174	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	81002	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	15998	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4122034	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	19622140	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	132246	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3636043	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16118343	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-5257034	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3089704	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-8346738	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-8346738	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	42477358	usd
CY2021Q2	MYMD	Modification Of Pre Merger Stock Options ModificationOfPreMergerStockOptions	4188315	usd
CY2021Q2	MYMD	Modification Terms Of Pre Merger Stock Options ModificationTermsOfPreMergerStockOptions	15036051	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-18092336	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	31074335	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	31074335	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7758077	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21182040	usd
	MYMD	Accrued Interestdividends AccruedInterestdividends	4496	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	608460	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-3649	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	41447	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-145	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-41447	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	180258	usd
	MYMD	Stock Option Modification Expenses StockOptionModificationExpenses	15036051	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	208332	usd
	MYMD	Options Issued To Nonemployees OptionsIssuedToNonemployees	4916	usd
	MYMD	Restricted Stock Units To Nonemployees RestrictedStockUnitsToNonemployees	15998	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	265060	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	557279	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1854909	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1988204	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	943	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	278	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5934245	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8258496	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6548	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	10137	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6500000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9983176	usd
	MYMD	Net Cash Received In Business Combination NetCashReceivedInBusinessCombination	1380852	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6493452	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11353891	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	3062444	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	120000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1826137	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1116307	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	559207	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1979088	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	555567	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	148284	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1115174	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2127372	usd
	us-gaap	Interest Paid Net InterestPaidNet	271800	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	53196	usd
	MYMD	Other Asset Investment OtherAssetInvestment	1500000	usd
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-2
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_z1u9b3g0qlDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b) <span id="xdx_86B_z1LMFoxN7cS9">Use of Estimates and Judgments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes for recording research and development expenses, impairment of intangible assets and the valuation of share-based payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-1999	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-3649	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6500000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9983176	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zJKgzkLWNpS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(h) <span id="xdx_868_zlvjSk9CMAO4">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash on deposit with financial institutions and accounts receivable. At times, the Company’s cash in banks is in excess of the FDIC insurance limit. The Company has not experienced any loss as a result of these cash deposits. These cash balances are maintained with three banks as of June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	170226	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	149009	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	61519	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	53240	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	109792	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	95911	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	19260	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	12439	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	36231	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	174877	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	31088	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P31Y
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100	pure
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	37547	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	77005	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	5814	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	120366	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1086	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	193731	usd
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12543300	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10136128	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12543300	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10136128	shares
	MYMD	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P1Y1M24D
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zoZOGV8E4e13" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(t) <span id="xdx_860_zQJ9dxa0aq7c">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform to the current year’s presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1115174	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4505825	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7758077	usd
CY2022Q2	MYMD	Working Capital WorkingCapital	4089352	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16118343	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86319645	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5934245	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7758077	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1854909	usd
CY2022Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2618109	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	867518	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	223426	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	119108	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2841535	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	986626	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4176737	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.59
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.59
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y3M14D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	14493284	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	300000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.41
	MYMD	Weighted Average Remaining Contractual Term Granted WeightedAverageRemainingContractualTermGranted	P6Y18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4476737	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.64
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.64
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4276737	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.56
	MYMD	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	2.58
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y10M20D
	MYMD	Unamortized Stock Option Expenses UnamortizedStockOptionExpenses	703772	usd
	MYMD	Unamortized Stock Option Expenses UnamortizedStockOptionExpenses	0	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	11576	shares
CY2021Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	11576	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.59
CY2021Q4	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	29982	usd
CY2022Q2	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	50000	usd
CY2021Q2	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	42000	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	98000	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	71000	usd
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03	pure
CY2022Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	11849	usd
CY2021Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2888	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	20598	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2888	usd

Files In Submission

Name	View Source	Status
0001493152-22-022611-index-headers.html	Edgar Link	pending
0001493152-22-022611-index.html	Edgar Link	pending
0001493152-22-022611.txt	Edgar Link	pending
0001493152-22-022611-xbrl.zip	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mymd-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
mymd-20220630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
mymd-20220630_def.xml	Edgar Link	unprocessable
mymd-20220630_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
mymd-20220630_pre.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNFA
TNF Pharmaceuticals, Inc. Stock $tnfa

2022 Q3 Form 10-Q Financial Statement

#000149315222022611 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNFA TNF Pharmaceuticals, Inc. Stock $tnfa

2022 Q3 Form 10-Q Financial Statement

#000149315222022611 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNFA
TNF Pharmaceuticals, Inc. Stock $tnfa